David Mankoff
Professor University of Pennsylvania
David Mankoff, MD, PhD, is a leading authority in nuclear medicine and PET imaging and a pioneer of whole-body PET. He is the Gerd Muehllehner Professor of Radiology and Vice Chair of Research at the University of Pennsylvania Perelman School of Medicine, and Associate Director for Education and Research at the Abramson Cancer Center. Dr. Mankoff played a key role in developing the PennPET Explorer and has made seminal contributions to quantitative and translational cancer imaging, particularly in breast cancer. A long-standing NIH-funded investigator, he has held numerous national leadership roles and has received multiple honors, including RSNA Honored Educator and the Academy of Radiology Research Distinguished Investigator Award.
Seminars
- Exploring alpha emitter biology using lead-212 and astatine-211 beyond DNA damage
- Linking molecular pathways to cellular response
- Informing therapeutic strategies through mechanistic insights from lead-212 and astatine-211
Step inside a candid, forward-looking conversation with the field’s scientific leaders as they dissect what the data has – and hasn’t – told us about radiopharmaceuticals heading into 2026. Challenge
assumptions, explore inflection points, and put your questions directly to the experts shaping the next wave of innovation, regulation, and clinical design
- Which scientific assumptions about radiopharmaceutical behavior have held up under clinical data through 2026 – and which are now clearly incomplete or wrong?
- Are current pharmacokinetic and dosimetry models sufficiently predictive for decision-making, or are we still over-relying on empirical iteration in the clinic?
- What is needed in the field to continue investment and movement?
- What lessons from recent late-stage programs should be influencing how we design first-in-human studies today?
- Does existing regulatory paradigms adequately reflect the unique risk–benefit calculus of radiopharmaceuticals, or is misalignment now a rate-limiting step?
- Which manufacturing and supply-chain constraints are a fundamentally scientific problem – and which require more infrastructural changes?
- Looking ahead, what scientific bottleneck is most likely to determine winners and failures in radiopharmaceuticals beyond 2026?
